Affiliation:
1. N.I. Pirogov Russian National Research Medical University, Moscow
Abstract
Aim. To compare the effectiveness of urapidil and enalaprilat in cardiac patients with complicated hypertensive crise (HC), including the effect of the medications on renal function. Material and methods. During 6 months, 70 patients with essential arterial hypertension (EAH), hospitalised with a diagnosis of complicated HC, were included in the study. Results. The therapy response rates were significantly higher in the urapidil vs. enalaprilat group (96,7% vs. 73,3%, p<0,001). During the first hour of the urapidil treatment, the levels of systolic blood pressure (SBP) decreased from 210,5±13,6 to 157,8±8,3 mm Hg (p<0,05), while the levels of diastolic blood pressure (DBP) decreased from 115,7±8,5 to 86,9±9,1 mm Hg (p<0,05). In the enalaprilat group, the respective SBP and DBP reduction was from 208,1 to 182,5 mm Hg (p<0,05) and from 114,8 to 95,0 mm Hg (p<0,05). Mean BP levels in the urapidil and enalaprilat groups decreased from 147,3±6,3 to 101,7±6,4 mm Hg and from 145,9±6,1 to 118,4±7,3 mm Hg, respectively. Over 6 hours, urapidil group patients demonstrated a more prolonged, sustained antihypertensive effect. Both medications did not affect heart rate (HR) levels. In neither group, clinically significant adverse effects were registered. The changes in glomerular filtration rate (GFR) or natriuresis were non-significant. Since after 6 hours, the patients were administered other combination therapy, the risk of acute vascular events was assessed during the following hours (up to 72 hours). No cases of acute cerebrovascular events or acute myocardial infarction were registered in either study group. Conclusion. Urapidil was more effective than enalaprilat in terms of responder number per 1 dose or BP reduction rate. Both medications did not affect HR, GFR, or natriuresis.
Subject
Cardiology and Cardiovascular Medicine
Reference25 articles.
1. Arutyunov G.P., Oganezova L.G. Giperfil'trtsiya v klinicheskoi praktike. Klin nefr 2009; 1: 29–40.
2. Shal'nova S.A., Balanova Yu.A., Konstantinov V.V. i dr. Arterial'naya gipertoniya: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniya sredi naseleniya Rossiiskoi Federatsii. Rossiiskii kardiologicheskii zhurnal 2006; 4: 45–50.
3. Global Health risks. Mortality and burden of disease attributable to selected major risks. Geneva, World Health Organization 2009.
4. Varonj, Marik P.E. The diagnosis and management of hypertensive crises. Chest 2000; 118: 214–27.
5. Vaughan C.J, Delanty N. Hypertensive emergencies. Lancet 2000; 356: 411–7.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献